The European drugs regulator said on Friday it was reviewing anti hair-loss drugs, including Organon's Propecia and its ...

Summit Therapeutics Inc. may have a potential successor to Merck's Keytruda with strong clinical data from China, but awaits ...

Societe Generale has recently reduced Merck & Co Inc (MRK) stock to Sell rating, as announced on March 11, 2024, according to Finviz. Earlier, on January 4, 2024, TD Cowen had raised the stock from a ...

The European drugs regulator said on Friday it was reviewing anti hair-loss drugs, including Organon's Propecia, for the ...

BeiGene has officially launched its PD-1 cancer drug Tevimbra in the U.S. more than six months after receiving a much-delayed ...

Mark Cuban, Reid Hoffman and other big names in business joined with Vice President Harris’s campaign for the launch of ...

IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, off-the-shelf, immune-modulating therapeutic cancer vaccines based on its T-win ® platform, today announced two ...

Kineta, Inc. (OTC Pink: KANT) , a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that its ...

Summit Therapeutics (NASDAQ: SMMT). This California-based biotech is developing a cancer medicine that has produced excellent clinical trial results in one area where Keytruda is the leader. Summit ...

Vice President Kamala Harris allies in the business community are trying to give her a boost over Donald Trump.

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $144.12, ...

Hot on the tail of AstraZeneca’s Imfinzi, Bristol Myers Squibb’s PD-1/L1 inhibitor Opdivo has expanded its non-small cell lung cancer (NSCLC) net with an ...